Vol. 3 No. 4 (2023)
Reimbursement Reviews

Belimumab (Benlysta)

decorative image

Published April 10, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses belimumab 400 mg per 20 mL vial and 120 mg in 5 mL vial lyophilized powder for IV infusion.
  • Indication: Indicated in addition to standard therapy for the treatment of active lupus nephritis in adult patients.